Septic shock secondary to β-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy

International Journal of Artificial Organs

Volumn 37, Issue 5, 2014, Pages 422-426

  Hetz, Hubert ^a   Berger, Reinhard ^a   Recknagel, Peter ^b   Steltzer, Heinz ^a  

^a AUVA Soziale Unfallversicherung   (Austria)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Cytokine adsorption; Multiorgan failure; Necrotizing fasciitis; Sepsis; Septic shock

Indexed keywords

DIAGNOSIS; INTENSIVE CARE UNITS; PATIENT REHABILITATION; SURGERY;

ANIMAL STUDIES; CLINICAL TRIAL; CYTOKINE ADSORPTION; CYTOKINES; INFLAMMATORY RESPONSE; MULTIORGAN FAILURE; NECROTIZING FASCIITI; OLDER FEMALE; SEPSIS; SEPTIC SHOCKS;

VENTILATION;

AMPICILLIN; FOSFOMYCIN; HYPERTENSIVE AGENT; INTERLEUKIN 6; NORADRENALIN; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; BETA HEMOLYTIC STREPTOCOCCUS; BLOOD FILTER; CASE REPORT; FEMALE; HEMOFILTRATION; HUMAN; HYPOTENSION; INFLAMMATION; KIDNEY FAILURE; LUNG INSUFFICIENCY; METABOLIC ACIDOSIS; MIDDLE AGED; MULTIPLE ORGAN FAILURE; NECROTIZING FASCIITIS; OUTCOME ASSESSMENT; SEPTIC SHOCK; THROMBOCYTOPENIA; ADSORPTION; COMPLICATION; FASCIITIS, NECROTIZING; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; SURGICAL WOUND INFECTION; TREATMENT OUTCOME;

ADSORPTION; ANTI-BACTERIAL AGENTS; FASCIITIS, NECROTIZING; FEMALE; HUMANS; MIDDLE AGED; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS; SURGICAL WOUND INFECTION; TREATMENT OUTCOME;

EID: 84903144701     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.5301/ijao.5000315     Document Type: Article

References (19)

1. Rimmelé T, Kellum JA. Clinical review: blood purification for sepsis. Crit Care. 2011;15(1):205. Published online February 16, 2011.
2. Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P. High-volume haemofiltration in human septic shock. Intensive Care Med. 2001;27(6):978-986.
3. Honore PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med. 2000;28(11):3581-3587.
4. Cole L, Bellomo R, Hart G, et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med. 2002;30(1):100-106.
5. Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaut E; Hemofiltration and Sepsis Group of the Collège National de Réanimation et de Médecine d'Urgence des Hôpitaux extra-Universitaires. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med. 2009;37(3):803-810.
6. Heering P, Morgera S, Schmitz FJ, et al. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intensive Care Med. 1997;23(3):288-296.
7. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303-1310.
8. Engel C, Brunkhorst FM, Bone HG, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med. 2007;33(4):606-618.
9. Fisher CJ Jr, Agosti JM, Opal SM, et al; The Soluble TNF Receptor Sepsis Study Group. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med. 1996;334(26):1697-1702.
10. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995; 273(12):934-941.
11. Fisher CJ Jr, Slotman GJ, Opal SM, et al; IL-1RA Sepsis Syndrome Study Group. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med. 1994;22(1):12-21.
12. Peng ZY, Carter MJ, Kellum JA. Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med. 2008;36(5):1573-1577.
13. Kellum JA, Song M, Venkataraman R. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med. 2004;32(3):801-805.
14. Peng ZY, Wang HZ, Carter MJ, et al. Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis. Kidney Int. 2012;81(4):363-369.
15. Spittler A, Razenberger M, Kupper H, et al. Relationship between interleukin-6 plasma concentration in patients with sepsis, monocyte phenotype, monocyte phagocytic properties, and cytokine production. Clin Infect Dis. 2000; 31(6):1338-1342.
16. Peng ZY, Carter MJ, Kellum JA. Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med. 2008;36(5):1573-1577.
17. Kellum JA, Kong L, Fink MP, et al; GenIMS Investigators. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007; 167(15):1655-1663.
18. Osuchowski MF, Welch K, Siddiqui J, Remick DG. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol. 2006;177(3):1967-1974.
19. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest. 1993;103(2):565-575.